Early-stage biotechs with limited funds must balance the need for quick data with building a solid IND package. The solution is to run two tracks in parallel: one for immediate R&D experiments and another dedicated to the methodical, long-term planning required for regulatory submission.

While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

Since most biotech programs fail (as few as 1 in 10 succeed), a company's survival depends on running a portfolio of multiple programs simultaneously. This requires the discipline to quickly terminate unsuccessful projects and the foresight to have subsequent programs already underway.

In ROI-focused cultures like financial services, protect innovation by dedicating a formal budget (e.g., 20% of team bandwidth) to experiments. These initiatives are explicitly exempt from the rigorous ROI calculations applied to the rest of the roadmap, which fosters necessary risk-taking.

Categorize all R&D work into four buckets: Health (maintenance), Innovation (new value), Parity (catch-up), and Modernization (tech debt). This "HIPM" framework clarifies where resources are going and enables leaders to make purposeful, annual budget shifts into the innovation category.

In a scaling company, a CRO must balance hitting immediate targets with building for the future. An effective model is the 70/30 split: 70% of time is focused on closing deals and hitting the quarterly number, while the other 30% is invested in creating the repeatable processes required for the next growth phase.

The primary operational difference between biotech and big pharma isn't just budget size, but how resource constraints force radical prioritization. The entire biotech organization must align on three or four critical, needle-moving goals tied to the next financing catalyst, a level of focus often diffused in larger companies.

CRISPR's CEO suggests a specific financial rule: never spend more than 11% of market cap in one year. Spending above 14-15% risks a 'dilution spiral,' while spending only 6-7% means you aren't taking enough aggressive risks. This provides a clear guardrail for R&D investment.

Given that 90% of drugs fail in the clinic, the most critical innovation isn't a single brilliant idea. It's building a company with the operational efficiency and financial runway to conduct all ten necessary experiments to find the one that will succeed.